Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
JSKN027 will become the first ADC with this mechanism to enter human trials.
BeOne terminates a MUC1-targeting project.
A binary Xpovio catalyst is set for March.
Welireg, Padcev, and a surprise fillip for Flare.
Two new pivotal Chinese first-line trials have started in lung cancer.
